Background
Acute renal failure (ARF) is one of the commonest complications of hospitalisation, with an overall incidence of up to 7%, 1 rising towards 15% in the intensive care unit (ICU). 2 ARF independently predicts mortality, 3 to which it contributes directly largely through 'non-renal' effects such as bleeding and sepsis. 4 Prompt action can save lives and nephrons; because of this potential reversibility it is important to differentiate ARF from chronic renal failure (CRF) ( Table 1) .
Acute renal failure on the intensive care unit
ARF occurring on the ICU appears to be a distinct entity. In non-ICU ARF, the kidney is usually the only failed organ and the mortality is less than 5-10%. 5, 6 In contrast, ICU ARF is often associated with sepsis and with non-renal organ system failure, 7 with mortality rates of over 50%, rising to 80% when renal replacement therapy (RRT) is required. 8 Predictably, death rates increase with increasing number of failing organ systems 8 but over 65% of survivors recover renal function and discontinue dialysis. 8 ICU ARF also differs in terms of likely aetiology, with 76% (vs 38% non-ICU ARF) primarily due to acute tubular necrosis (ATN) (Fig 1) . 7 
Acute tubular necrosis
Hypoxic tubular injury involves changes in both function 9 and morphology. 10 Recovery involves tubular cell regeneration and differentiation 11 and is associated with the activation of growth response genes and the release of growth factors. 11 The renal failure phase of ATN generally lasts 7-21 days. 12 Recovery time depends on the duration and severity of the initial insult and the presence of further insults; 12 this may be compounded by a loss of renal autoregulatory vasodilatation that exposes the renal microcirculation to even modestly reduced systemic perfusion. Most survivors with ATN return towards their baseline level of renal function, although persistent loss of renal function is more likely in those with pre-existing CRF or prolonged ARF due to repeated renal insults. 13 Numerous pharmacological strategies, including loop diuretics and 'renal dose' dopamine, have failed to ameliorate human ATN despite some experimental success. [14] [15] [16] [17] [18] [19] [20] 
Diagnosis
A practical approach to diagnosis ( 
Urinalysis
Urinalysis and urine microscopy play an important role in diagnosis. The presence of haematuria, especially with proteinuria, may indicate glomerulonephritis as well as catheter trauma or urine infection. Urine microscopy will show red cell casts, indicating glomerular bleeding. Muddy brown granular casts are highly suggestive of ATN. However, urinalysis may be relatively bland.
Urine chemistry
Urine chemistry is traditionally recommended to distinguish pre-renal ARF from ATN (Table 3 ), but in practice it is often diagnostically irrelevant. Haemodynamically-mediated ARF represents a continuum from an appropriate renal response (pre-renal ARF) to renal cell injury (ATN). The response to improved renal perfusion (which will not ameliorate ATN) can usually differentiate the two before chemistry results are available. One niche role may be in distinguishing the avid sodium retention of the hepatorenal syndrome from ATN, with implications for both management and outcome. 
Ultrasonography
The mainstay of diagnosis of post-renal ARF is ultrasonography which may be normal in early obstruction (when the renal tract is relatively non-compliant) and in the presence of ATN (the obstructed tract needs urine to dilate). Repeated scanning is recommended when there is a high index of suspicion.
Management
There are five key aspects of management of the patient with ICU ARF: 
Treatment of the precipitating condition
This includes the medical and surgical management of precipitants and the withdrawal of offending drugs. The possibility of post-renal ARF should be considered and treated.
Optimisation of effective circulating volume
Intravascular volume status may be assessed through:
• clinical examination • examination of fluid balance charts • estimation of insensible losses • daily weights (when reliable), and • invasive monitoring.
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Clinical 
Pre-renal ARF ATN
Urine Na + (mmol/l) <20 >40
Urine osmolarity (mosm/l) >500 <350
Urine/plasma urea >8 <3
Urine/plasma creatinine >40 <20 FENa* (%) <1 >2
*FENa (%) = (urine Na × plasma creatinine) ÷ (plasma Na × urine creatinine) × 100. Urine Na + is less accurate than FENa as it is also affected by degree of water reabsorption. FENa may be low in acute glomerulonephritis and early ATN. A FENa of 1-2% is compatible with both pre-renal ARF and ATN.
Use of diuretics and dopamine may confound interpretation. ATN = acute tubular necrosis; FENa = fractional excretion of sodium. 
Pharmacology
Avoid nephrotoxins and give drug doses appropriate to the level of renal function (check the British National Formulary). Both iv sodium bicarbonate and N-acetylcysteine may have a role in contrast nephropathy prophylaxis.
Medical management of complications
The widespread availability of RRT in critical care units has transformed the management of ARF. However, medical management is still important in the initial stabilisation of the patient with life-threatening complications. Fluid overload may be managed with iv furosemide (doses up to 250 mg), and a good diuretic response may be maintained with an iv infusion at a rate of 10-20 mg/hour. Daily doses higher than 1 g carry risks of ototoxicity and prolonged use in the critically ill should be avoided. 21 Hyperkalaemia can be managed with iv infusions of calcium gluconate, dextrose and insulin, furosemide or sodium bicarbonate, although the last may result in salt loading. Nebulised salbutamol may be effective in the emergency treatment of severe hyperkalaemia but is efficacious only at doses of 10-20 mg. again been focused on its traditional indication. 22 RRT relies on two physical processes: convection and diffusion:
Renal replacement therapy
Convection. Convection involves hydrostatic plasma water removal across a semipermeable membrane (also termed ultrafiltration (UF)). Solute follows by solvent drag. High volume UF is combined with simultaneous fluid replacement (haemofiltration) to enhance solute removal and achieve a euvolaemic state (by altering removal or replacement rates). Larger solutes are removed relatively efficiently, smaller solutes (eg urea, potassium) less so, with this technique.
Diffusion. The converse applies for diffusive solute removal in haemodialysis (HD). Fluid removal in HD is achieved by the addition of a small amount of ultrafiltration. Both diffusive and (major) convective solute removal can be combined in haemodiafiltration. However, the advantages of enhanced larger molecular clearances are disputed. Firm links between RRT dose and outcome are established only for small solutes. Figure 2 graphically illustrates the mechanics of these modalities and Table 4 describes nomenclature and use.
Many ICUs have developed experience in continuous RRT (CRRT) over the last decade. 24 This method spreads solute clearance as well as fluid removal over a much longer time frame. Intuitively, it may be seen as the modality of choice (Table 5 ), but there are no convincing data to suggest a superior outcome to conventional dialysis. 25, 26 The removal of inflammatory mediators during CRRT has been mooted as a potential advantage over intermittent haemodialysis (IHD). There is, however, a lack of consistent human data and a disparity between the high endogenous turnover of these mediators and their negligible extracorporeal clearance. 27 In the absence of urgent indications for RRT (Table 6 ) there is no consensus over its timing of initiation. 28 An argument for early intervention before overt uraemia has developed may be countered
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Clinical Medicine by concerns that dialysis may delay the recovery of renal function, 29 although this may be less of a problem with CRRT. 30 In practice, many ICUs commence RRT as soon as it is clear that irreversible renal failure has occurred.
Technical considerations. Certain technical considerations apply across modalities:
• The membrane material used in dialysers/haemofilters: although outcome data are conflicting, most practitioners would choose more biocompatible membranes that are less likely to promote complement and granulocyte activation.
• The choice of dialysate or replacement fluid: CRRT solutions may be lactate-based or bicarbonate-based. However, the former may not correct acidosis when hepatic perfusion and lactate conversion are impaired. IHD dialysate is now almost uniformly bicarbonate-based.
Dose.
The question of what constitutes an adequate dose of RRT remains to be fully answered. Some evidence links dose with outcome, [31] [32] [33] but the optimal methods of prescribing and assessing delivery remain unclear. Dosing IHD may prove to be more complex. 34 Current evidence suggests that daily IHD may be desirable 33 and that a urea reduction ratio (100 × (1 -post-dialysis urea/predialysis urea)) above 58% is preferable. 31 For CRRT, ultrafiltration rates (for continuous venovenous haemofiltration (CVVH)), dialysate flow rates (CVVHD) or a summation of the two (CVVHDF) should be prescribed at 35 ml/hour/kg body weight. 32
Conclusions
ARF occurring on the ICU remains a devastating condition; the predominant aetiology is ATN in the context of multiple organ failure. Its optimal management relies on the treatment of precipitating factors, optimisation of effective circulating volume and judicious use of RRT. A structured approach to diagnosis will aid in identifying more esoteric aetiologies which may require quite different management.
